<DOC>
	<DOCNO>NCT01468688</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose and/or recommend phase 2 dose combination imatinib BKM120 treatment 3rd line GIST patient .</brief_summary>
	<brief_title>A Dose-finding Study Combination Imatinib BKM120 Treatment 3rd Line GIST Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient ≥ 18 year age 2. WHO performance status ( PS ) 02 3 . Histologically confirm diagnosis GIST unresectable metastatic 4 . Available tissue specimen : Doseescalation cohort : patient must available archival tumor tissue ship course study Doseexpansion cohort : patient must available archival tumor tissue ship course study must agree fresh pretreatment biopsy . 5 . Failed prior therapy imatinib follow sunitinib treatment unresectable metastatic GIST . Note follow specific criterion two phase trial : Doseescalation cohort : patient fail prior therapy imatinib fail therapy sunitinib . Treatment failure may due either disease progression therapy ( imatinib sunitinib ) intolerance therapy ( sunitinib ) . Doseescalation cohort patient may additional line therapy limit imatinib sunitinib . Doseexpansion cohort : patient must document disease progression imatinib sunitinib . In addition , patient may two line prior therapy ( i.e . treatment imatinib follow treatment sunitinib ) . Adjuvant imatinib count prior course imatinib purpose criterion 1 . Previous treatment PI3K inhibitor 2 . A medical history follow mood disorder judge Investigator psychiatrist : Medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt thought , homicidal thought ( immediate risk harm others ) ≥ CTCAE grade 3 anxiety 3 . When complete patient questionnaire screen : Meets cutoff score ≥ 10 nine item depression scale Patient Health Questionnaire ( PHQ9 ) cutoff ≥ 15 Generalized Anxiety Disorder Assessment ( GAD 7 ) mood scale respectively , Selects positive response 1 , 2 , 3 question number 9 regard potential suicidal thought ideation PHQ9 ( independent total score PHQ9 ) 4 . Severe and/or uncontrolled concurrent medical condition , opinion investigator could cause unacceptable safety risk compromise compliance protocol ( e.g . acute chronic liver , pancreatic , severe renal disease consider unrelated study disease , chronic pulmonary disease include dyspnea rest cause ) . 5 . Poorly control diabetes mellitus ( define HbA1c &gt; 8 % ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Imatinib mesylate</keyword>
	<keyword>BKM120</keyword>
	<keyword>GIST</keyword>
</DOC>